TGFB1 and chronic kidney disease: Apabetalone reduced levels of transcriptional targets of TGF-β1 specifically in plasma of CKD subjects, suggesting apabetalone can suppress pro-fibrotic transcriptional signatures induced by TGF-β1 in human subjects.